Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2875358 plus Erlotinib vs Erlotinib in EGFR-mutant Metastatic NSCLC
2024-514268-18-00Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, randomised trial of emibetuzumab and erlotinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Progression-free survival. Started Nov 2024; status: completed.
02
Drugs
emibetuzumaberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-514268-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514268-18-00.